CSIMarket
 
Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

Cytokinetics Incorporated's Customers Performance

CYTK

 
CYTK's Source of Revenues During the corresponding time, Cytokinetics Incorporated revenue deteriorated by -84.97 % year on year, sequentially revenue fell by -56.4 %. While revenue at the Cytokinetics Incorporated's corporate clients

List of CYTK Customers




for the same period Cytokinetics Incorporated revnue deteriorated by -84.97 % year on year, sequentially revnue fell by -56.4 %.

List of CYTK Customers





Cytokinetics Incorporated's Comment on Sales, Marketing and Customers





  News about Cytokinetics Incorporated Contracts

Advancing Cardiovascular Research: A New Initiative to Empower Historically Underrepresented Groups in Clinical Trials

In a groundbreaking partnership, Cytokinetics, The Mended Hearts, Inc., and WomenHeart have joined forces to launch a revolutionary initiative aimed at increasing engagement in cardiovascular clinical trials. Recognizing the importance of inclusive research, Cytokinetics has generously provided grant funding to each organization to foster participation among historically underrepresented groups. This collaboration is poised to be a catalyst for change in the field of cardiovascular medicine, empowering individuals who have been historically marginalized in clinical trial research.Fact 1: Cytokinetics' Grant Funding to Boost Clinical Trial EngagementCytokinetics, a pioneering biopharmaceutical company, has ma...

Cytokinetics Allocates $100,000 in Annual Communications Grant to Boost Patient Advocacy Outreach

Cytokinetics, the renowned pharmaceutical company, has announced the recipients of its Sixth Annual Communications Grant Program. In a noteworthy philanthropic step, a total of $100,000 has been awarded to five chosen patient advocacy organizations. This funding is aimed at strengthening their communications and enabling them to enhance their community outreach efforts more effectively.Patient advocacy organizations hold a vital role in the healthcare ecosystem. Their commitment in raising awareness about various health conditions, propagating essential health information, and serving as the voice of patients is remarkable. The financial aid from Cytokinetics will undoubtedly empower these organizations to c...

Cytokinetics Presents Promising Data on Aficamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy and Updates on Reldesemtiv's Efficacy in ALS

Cytokinetics, a leading biopharmaceutical company specializing in the development of novel therapies for cardiovascular and neuromuscular diseases, recently presented new data at CMR 2024 regarding the clinical trial of Aficamten in patients with obstructive hypertrophic cardiomyopathy. These findings demonstrate favorable structural remodeling, improvements in cardiac function, and stabilization of fibrosis in patients receiving Aficamten treatment. Additionally, Cytokinetics provided an update on the efficacy of Reldesemtiv in amyotrophic lateral sclerosis (ALS) based on the results from COURAGE-ALS trial.Aficamten in Obstructive Hypertrophic Cardiomyopathy:The results from the FOREST-HCM trial extension, ...

Paving the Way for Groundbreaking Treatment: Aficamten's Triumph in Obstructive Hypertrophic CardiomyopathyDisclaimer: This article is not intended to replace professional medical advice. Always consult with healthcare professionals before making any treatment decisions.

Abstract:Obstructive hypertrophic cardiomyopathy (HCM) is a complex and potentially life-threatening cardiac disorder affecting a significant proportion of the global population. In recent years, there has been a growing need to identify effective treatment options to alleviate symptoms and improve patient outcomes. This article aims to provide an extensive analysis of the SEQUOIA-HCM Phase 3 clinical trial, evaluating the efficacy and safety of aficamten in patients with obstructive HCM. The trial results demonstrate a statistically significant and clinically meaningful increase in the primary efficacy endpoint at 24 weeks of treatment, with consistent improvement observed across all prespecified subgroups....

Hope Dashed for ALS Patients: Cytokinetics' COURAGE-ALS Study Fails to Show Promise in Halting Functional Decline


Introduction
In a recent press release, Cytokinetics, a leading biopharmaceutical company, unveiled the results from its renowned clinical trial, COURAGE-ALS, at the 34th International Symposium on ALS/MND. The highly anticipated study examined the potential of reldesemtiv, a novel therapeutic compound, to demonstrate positive effects on the functional decline associated with Amyotrophic Lateral Sclerosis (ALS) patients. Unfortunately, Cytokinetics announced that reldesemtiv had no significant impact on the primary endpoint of change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) or key secondary endpoints.
Understanding Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressi...












CYTK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Cytokinetics Incorporated 5,180.71 7.82 -526.73 202
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com